Categories: News

CRISPR Therapeutics to Present at the 2022 Bank of America Healthcare Conference

ZUG, Switzerland and CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the 2022 Bank of America Healthcare Conference on Wednesday, May 11, 2022, at 4:40 p.m. PT.

A live webcast of the event will be available on the “Events & Presentations” page in the Investors section of the Company’s website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company’s website for 14 days following the presentation.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com

Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com

Staff

Recent Posts

KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

26 mins ago

Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2024

DORADO, PUERTO RICO / ACCESSWIRE / March 18, 2024 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv"…

27 mins ago

West Island Brands Acquires Contract to Supply Bio Products Internationally

Toronto, Ontario--(Newsfile Corp. - March 18, 2024) - West Island Brands Inc. (CSE: WIB) (FSE:…

5 hours ago

NextGen Healthcare Chosen by United Medical Centers to Support Integrated Care Delivery in Communities at United States-Mexico Border

Growing Need for Integration Led FQHC to Select NextGen HealthcareREMOTE-FIRST COMPANY/EAGLE PASS, Texas--(BUSINESS WIRE)--#NextGenHealthcare--Driven by…

6 hours ago

The Assistance Fund Opens New Program for Heart Failure

Copay Assistance From The Assistance Fund Now Available for Eligible People Living With Heart FailureORLANDO,…

6 hours ago

US Med-Equip Earns CIO 100 Award for IT Innovation With New AI Solution Helping Clinicians Secure Medical Equipment on Demand

Life-Saving Equipment Delivered to Patients in Record Time, Lower Cost at Hospitals Using Award-Winning GoUSME…

6 hours ago